Clinical Trials Logo

Recurrent IgA Nephropathy clinical trials

View clinical trials related to Recurrent IgA Nephropathy.

Filter by:
  • None
  • Page 1

NCT ID: NCT02571842 Recruiting - Clinical trials for Recurrent IgA Nephropathy

Rituximab in Recurrent IgA Nephropathy

Start date: January 2012
Phase: Phase 4
Study type: Interventional

Currently, the treatment options of recurrent IgA nephropathy (IgAN) are conflicting and largely based on expert opinions. Consequently, the recent KDIGO clinical practice guideline for the care of kidney transplant recipients has concluded that there are no definite strategies for prevention and treatment. However, recurrent IgAN in the transplanted kidney is common and may contribute to graft loss, in particular, if cresentic formation, extra- or endocapillary proliferation were presented in kidney pathology. Herein, the investigators assume that rituximab, anti-CD20 Ab agent, can reduce circulating IgA with subsequently decrease rate of polymeric forms of IgA deposition in glomerular capillaries. Therefore, the investigators speculate that rituximab may have potential effect to reduce circulating polymeric forms of IgA and slow progression of recurrent IgAN.